Synbiotics Decrease the Incidence of Septic Complications in Patients with Severe SIRS: A Preliminary Report

被引:66
作者
Shimizu, Kentaro [1 ]
Ogura, Hiroshi [1 ]
Goto, Miki [1 ]
Asahara, Takashi [2 ]
Nomoto, Koji [2 ]
Morotomi, Masami [2 ]
Matsushima, Asako [1 ]
Tasaki, Osamu [1 ]
Fujita, Kieko [1 ]
Hosotsubo, Hideo [1 ]
Kuwagata, Yasuyuki [1 ]
Tanaka, Hiroshi [1 ]
Shimazu, Takeshi [1 ]
Sugimoto, Hisashi [1 ]
机构
[1] Osaka Univ, Grad Sch Med, Dept Traumatol & Acute Crit Med, Suita, Osaka 5650871, Japan
[2] Yakult Cent Inst Microbiol Res, Kunitachi, Tokyo 1860011, Japan
关键词
Gut; Flora; Short-chain fatty acid; pH; SIRS; Synbiotics; Probiotics; RANDOMIZED CLINICAL-TRIAL; LACTOBACILLUS-CASEI; INTESTINAL FUNCTION; DOUBLE-BLIND; GUT FLORA; INFECTION; THERAPY; MICROFLORA; PROBIOTICS; MICE;
D O I
10.1007/s10620-008-0460-2
中图分类号
R57 [消化系及腹部疾病];
学科分类号
100201 [内科学];
摘要
The purpose of this study was to evaluate if synbiotic therapy can correct the deteriorated gut flora and environment in patients with severe systemic inflammatory response syndrome (SIRS). Twenty-nine SIRS patients, who fulfilled a serum C-reactive protein (CRP) level > 10 mg/dl, received synbiotics (Bifidobacterium breve, Lactobacillus casei, and galactooligosaccharides) (S group) and were compared with previous observations in 26 patients without synbiotics (NS group). Analysis of fecal flora confirmed that patients in the S group had significantly greater levels of beneficial Bifidobacterium, Lactobacillus, and total organic acids (particularly short-chain fatty acids) than those in the NS group. The incidence of infectious complications such as enteritis, pneumonia, and bacteremia was significantly lower in the S group than in the NS group. Synbiotics maintain the gut flora and environment and decrease the incidence of septic complications in patients with severe SIRS. Further randomized controlled study is necessary to determine the effects of synbiotics.
引用
收藏
页码:1071 / 1078
页数:8
相关论文
共 41 条
[1]
Randomised clinical trial of synbiotic therapy in elective surgical patients [J].
Anderson, ADG ;
McNaught, CE ;
Jain, PK ;
MacFie, J .
GUT, 2004, 53 (02) :241-245
[2]
[Anonymous], P 1 INT C CULT COLL
[3]
Probiotic bifidobacteria protect mice from lethal infection with shiga toxin-producing Escherichia coli O157:H7 [J].
Asahara, T ;
Shimizu, K ;
Nomoto, K ;
Hamabata, T ;
Ozawa, A ;
Takeda, Y .
INFECTION AND IMMUNITY, 2004, 72 (04) :2240-2247
[4]
Increased resistance of mice to Salmonella enterica serovar Typhimurium infection by synbiotic administration of Bifidobacteria and transgalactosylated oligosaccharides [J].
Asahara, T ;
Nomoto, K ;
Shimizu, K ;
Watanuki, M ;
Tanaka, R .
JOURNAL OF APPLIED MICROBIOLOGY, 2001, 91 (06) :985-996
[5]
Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial [J].
Besselink, Marc G. H. ;
van Santvoort, Hjalmar C. ;
Buskens, Erik ;
Boermeester, Marja A. ;
van Goor, Harry ;
Timmerman, Harro M. ;
Nieuwenhuijs, Vincent B. ;
Bollen, Thomas L. ;
van Ramshorst, Bert ;
Witteman, Ben J. M. ;
Rosman, Camiel ;
Ploeg, Rutger J. ;
Brink, Menno A. ;
Schaapherder, Alexander F. M. ;
Dejong, Cornelis H. C. ;
Wahab, Peter J. ;
van Laarhoven, Cees J. H. M. ;
van der Harst, Erwin ;
van Eijck, Casper H. J. ;
Cuesta, Miguel A. ;
Akkermans, Louis M. A. ;
Gooszen, Hein G. .
LANCET, 2008, 371 (9613) :651-659
[6]
Effects of intestinal microflora and the environment on the development of asthma and allergy [J].
Björkstén, B .
SPRINGER SEMINARS IN IMMUNOPATHOLOGY, 2004, 25 (3-4) :257-270
[7]
DEFINITIONS FOR SEPSIS AND ORGAN FAILURE AND GUIDELINES FOR THE USE OF INNOVATIVE THERAPIES IN SEPSIS [J].
BONE, RC ;
BALK, RA ;
CERRA, FB ;
DELLINGER, RP ;
FEIN, AM ;
KNAUS, WA ;
SCHEIN, RMH ;
SIBBALD, WJ .
CHEST, 1992, 101 (06) :1644-1655
[8]
*CDCP, NAT NOS INF SURV SYS
[9]
Fallingborg J, 1999, DAN MED BULL, V46, P183
[10]
FULLER R, 1989, J APPL BACTERIOL, V66, P365